Lupin Signs Canada Licensing Pact with Spektus for Novel Antidepressant DeslaFlex
Mumbai: Global pharma major Lupin Limited has signed a licence and supply agreement with Spektus Pharma, a specialty pharmaceutical company, to commercialize the novel antidepressant DeslaFlex in Canada.
DeslaFlex™ is an innovative antidepressant formulation developed by Spektus using its proprietary Flexitab™ oral drug-delivery platform.
The strategic partnership combines Lupin’s established commercial footprint in Canada with Spektus’s expertise in developing differentiated and novel formulations. The collaboration aims to successfully introduce DeslaFlex™ in the Canadian market while building a platform for future launches. The agreement further strengthens Lupin’s central nervous system (CNS) portfolio with physician-endorsed, value-added therapies aligned with a supportive regulatory environment.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.